Explored as a possible aid for recovery and lean-mass preservation in frail or catabolic populations, though a Merck-sponsored Phase 2b trial in elderly hip-fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics, PMID 21067829) was halted early over a cardiac safety signal rather than demonstrating a clear functional benefit
Individual suitability varies, so a consultation is always the right starting point before beginning a series
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Tom MacLaren , a consultant psychiatrist at Re:Cognition Health based in London, said in an interview with Medical News Today
Rather than directly activating GABA-A receptors, the peptide appears to maintain homeostasis of the entire GABA receptor complex, preventing the desensitization and compensatory changes that produce tolerance and dependence
PMID 16314912
